Same-day labs available at our partner lab
The results of the phase 3a PIONEER TEENS study will underpin filings of the drug under the Ozempic and Rybelsus brand names before the end of 2026, and according to Novo Nordisk could become the first oral GLP-1 therapies approved for use in paediatric T2D patients
Start Your Weight Loss Journey Today Book a consultation with Dr
Areas We Serve Here are the primary service areas we serve, including statewide clinics: Medical Weight Loss Program Pricing & Inclusions InjectCo offers clear, upfront pricing for its physician-guided medical weight loss programs in Louisiana, with no hidden fees
Tesofensine vs GLP-1 Medications: A Comparison The best option depends on your medical history, metabolic profile, and tolerance
However, more severe skin and structural changes are seen in GLP-1 agonist patients with these risk factors 4 : Advanced age Prolonged obesity history Rapid weight loss Poor hydration Insufficient protein intake Treatments for GLP-1 face and skin GLP 1 face affects the composite of facial structure, from skin, volume to muscles